#None #Westport #Shareholder Value #Atrium Therapeutics #Yakira Capital

Yakira Capital Management Calls for Strategic Review at Atrium Therapeutics

Yakira Capital Management, Inc. has recently made headlines by urging Atrium Therapeutics, Inc. to launch an immediate strategic review. This call comes amid concerns about the substantial cash burn and the perplexing decision to issue equity at a much-depressed stock price. The firm is particularly pressing the board to consider strategic alternatives that could enhance shareholder value before more capital is committed.

Context of the Call

In early October, Atrium Therapeutics announced a $50 million private placement that included around 5.17 million common shares and pre-funded warrants for an additional 1.13 million shares, all priced at approximately $7.93 each. This announcement was met with skepticism from Yakira, who noted that Atrium's stock had already fallen significantly—nearly 44% from previous levels of about $14 per share. Yakira's management questioned why the company opted to raise capital during such a downturn rather than when the valuation was stronger.

Yakira's primary concern revolves around the impact of further dilution on long-term shareholder value. They are urging Atrium's board to explain the decision-making process that led to this capital raising and to explore options such as rights offerings, where existing shareholders could participate and mitigate their risk of dilution.

Evaluating Atrium's Value

The investment firm highlights three components that contribute to Atrium's overall value:
1. Net Cash: Yakira estimates that Atrium had approximately $254 million in net cash at the end of the third quarter, which translates to about $14.85 per share. With the stock trading below $8, investors are buying at a significant discount to this estimated cash value.
2. Bristol Myers Squibb Collaboration: Atrium's collaboration with Bristol Myers Squibb could yield up to $1.35 billion in research and development milestones. Yakira emphasizes that understanding the specifics of this agreement, including the spending cap, is crucial for shareholders to gauge Atrium's financial exposure.
3. Internal Development Pipeline: The company is developing promising candidates like ATR 1072 and ATR 1086. Shareholders should be aware that at current stock levels, the market seems to assign a negative value to these assets, and the board should explore potential partnerships or partnerships to unlock value.

Demand for Transparency

Yakira posits that Atrium’s lead program is still in the early stages of clinical development, with substantial financial commitments needed ahead of critical proof-of-concept results expected in late 2027. As development costs are likely to increase, shareholders have expressed a desire for more transparency regarding the capital requirements to achieve clinical milestones.

Yakira argues that if Atrium ultimately needs a strategic partnership or external capital to achieve the value of its programs, it raises the question of why shareholders are expected to shoulder all the risks associated with clinical trials.

Call to Action

y
In a letter addressed to Atrium's board, Yakira urged for immediate action:

• - Initiate a strategic review with the aid of independent financial advisors to assess options like partnerships or mergers.
• - Implement disciplined spending controls to preserve shareholder capital while transparently estimating necessary investments for clinical milestones.
• - Clarify the rationale behind recent financing decisions, ensuring that alternatives such as rights offerings were adequately considered.

Yakira emphasizes that a strategic review does not obligate the Board to accept any offers but is crucial for determining whether better risk-adjusted outcomes exist before committing more shareholder capital. The board's primary responsibility should be maximizing shareholder value, rather than just financing ongoing operations.

Conclusion

The time for decisive action is now, as delays could further dilute shareholder value. Yakira Capital Management believes a strategic examination and greater transparency are essential for justifying ongoing investments and fostering trust with shareholders as Atrium navigates its future development path.